APP and Alzheimer disease: To test the in vivo therapeutic effects of the lead peptoid, CPO_ Aβ17-21 P, we systematically treated APP/PS1 AD mice twice a week for four months with 0.20 mg of CPO_Aβ17-21 P per mouse (n = 11, 5 male, 6 female) or with vehicle saline (n = 10, 5 male, 5 female) as a control.